Starpharma Holdings
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The last earnings update was 84 days ago. More info.
Add to Portfolio Compare Print
- Starpharma Holdings has significant price volatility in the past 3 months.
SPL Share Price and Events
7 Day Returns
1 Year Returns
SPL Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Starpharma Holdings (SPL) | 0% | -4.5% | 18.5% | 2% | 82.9% | 85.5% |
| AU Pharmaceuticals | -2.1% | -5.8% | -3.5% | -28.9% | -38.3% | -26.6% |
| AU Market | 2.9% | 3.2% | 5.5% | 4.3% | 21% | 9.7% |
1 Year Return vs Industry and Market
- SPL outperformed the Pharmaceuticals industry which returned -28.9% over the past year.
- SPL underperformed the Market in Australia which returned 4.3% over the past year.
SPL Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Starpharma Holdings. This is due to cash flow or dividend data being unavailable. The share price is A$1.28.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Starpharma Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Starpharma Holdings's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in AUD | A$-0.03 |
| ASX:SPL Share Price ** | ASX (2019-05-21) in AUD | A$1.28 |
| Australia Pharmaceuticals Industry PE Ratio | Median Figure of 6 Publicly-Listed Pharmaceuticals Companies | 20.33x |
| Australia Market PE Ratio | Median Figure of 542 Publicly-Listed Companies | 16.09x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Starpharma Holdings.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ASX:SPL Share Price ÷ EPS (both in AUD) = 1.28 ÷ -0.03 |
-41.92x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Starpharma Holdings is loss making, we can't compare its value to the AU Pharmaceuticals industry average.
- Starpharma Holdings is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does
Starpharma Holdings's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -41.92x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts |
64.5%per year |
| Global Pharmaceuticals Industry PEG Ratio | Median Figure of 118 Publicly-Listed Pharmaceuticals Companies | 1.52x |
| Australia Market PEG Ratio | Median Figure of 359 Publicly-Listed Companies | 1.45x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Starpharma Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Starpharma Holdings's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in AUD | A$0.13 |
| ASX:SPL Share Price * | ASX (2019-05-21) in AUD | A$1.28 |
| Australia Pharmaceuticals Industry PB Ratio | Median Figure of 26 Publicly-Listed Pharmaceuticals Companies | 3.32x |
| Australia Market PB Ratio | Median Figure of 1,676 Publicly-Listed Companies | 1.65x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ASX:SPL Share Price ÷ Book Value per Share (both in AUD) = 1.28 ÷ 0.13 |
9.93x |
* Primary Listing of Starpharma Holdings.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Starpharma Holdings is overvalued based on assets compared to the AU Pharmaceuticals industry average.
Value checks
We assess Starpharma Holdings's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) Starpharma Holdings has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
SPL Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Starpharma Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
- Unable to compare Starpharma Holdings's earnings growth to the Australia market average as it is expected to be loss making during the next 1-3 years.
- Starpharma Holdings's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ASX:SPL Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts | 64.5% |
| ASX:SPL Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts | 70.8% |
| Australia Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 51.4% |
| Australia Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 32.2% |
| Australia Market Earnings Growth Rate | Market Cap Weighted Average | 7% |
| Australia Market Revenue Growth Rate | Market Cap Weighted Average | 3.2% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-06-30 | 27 | 1 | 0 | 2 |
| 2020-06-30 | 20 | 4 | -8 | 2 |
| 2019-06-30 | 6 | -10 | -13 | 2 |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 4 | -6 | -11 |
| 2018-09-30 | 5 | -8 | -11 |
| 2018-06-30 | 5 | -10 | -10 |
| 2018-03-31 | 5 | -12 | |
| 2017-12-31 | 4 | -18 | -13 |
| 2017-09-30 | 4 | -18 | -14 |
| 2017-06-30 | 4 | -17 | -15 |
| 2016-12-31 | 1 | -20 | -20 |
| 2016-09-30 | 3 | -19 | -20 |
| 2016-06-30 | 5 | -18 | -21 |
| 2016-03-31 | 5 | -17 | -22 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
All data from Starpharma Holdings Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-06-30 | -0.01 | -0.01 | -0.01 | 1.00 |
| 2020-06-30 | -0.01 | -0.01 | -0.01 | 1.00 |
| 2019-06-30 | -0.04 | -0.04 | -0.04 | 1.00 |
| Date (Data in AUD Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.03 |
| 2018-09-30 | -0.03 |
| 2018-06-30 | -0.03 |
| 2018-03-31 | -0.03 |
| 2017-12-31 | -0.04 |
| 2017-09-30 | -0.04 |
| 2017-06-30 | -0.04 |
| 2016-12-31 | -0.05 |
| 2016-09-30 | -0.06 |
| 2016-06-30 | -0.06 |
| 2016-03-31 | -0.06 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Starpharma Holdings will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Future performance checks
We assess Starpharma Holdings's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Starpharma Holdings has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
SPL Past Performance
How has Starpharma Holdings performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Starpharma Holdings does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Starpharma Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Starpharma Holdings's 1-year growth to the Global Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
All data from Starpharma Holdings Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 4.37 | -11.32 | 5.55 | 10.15 |
| 2018-09-30 | 4.67 | -10.80 | 5.11 | 10.36 |
| 2018-06-30 | 4.96 | -10.29 | 4.67 | 10.58 |
| 2018-03-31 | 4.65 | -11.70 | 4.62 | 11.73 |
| 2017-12-31 | 4.34 | -13.11 | 4.57 | 12.88 |
| 2017-09-30 | 3.99 | -14.17 | 4.28 | 13.88 |
| 2017-06-30 | 3.65 | -15.22 | 3.99 | 14.88 |
| 2016-12-31 | 1.38 | -19.59 | 3.84 | 17.14 |
| 2016-09-30 | 2.98 | -20.44 | 4.14 | 19.28 |
| 2016-06-30 | 4.57 | -21.29 | 4.45 | 21.42 |
| 2016-03-31 | 4.67 | -21.56 | 4.73 | 21.50 |
| 2015-12-31 | 4.70 | -20.45 | 4.31 | 20.84 |
| 2015-09-30 | 3.20 | -19.70 | 4.35 | 18.54 |
| 2015-06-30 | 1.70 | -18.95 | 4.39 | 16.25 |
| 2015-03-31 | 1.48 | -18.27 | 4.69 | 15.06 |
| 2014-12-31 | 1.27 | -17.60 | 4.99 | 13.87 |
| 2014-09-30 | 1.26 | -16.12 | 4.94 | 12.43 |
| 2014-06-30 | 1.25 | -14.64 | 4.89 | 10.99 |
| 2014-03-31 | 1.56 | -11.80 | 4.34 | 9.01 |
| 2013-12-31 | 1.86 | -8.97 | 3.79 | 7.03 |
| 2013-09-30 | 2.15 | -7.10 | 3.97 | 5.27 |
| 2013-06-30 | 2.43 | -5.23 | 4.15 | 3.51 |
| 2013-03-31 | 2.71 | -8.02 | 4.33 | 6.39 |
| 2012-12-31 | 2.99 | -10.81 | 4.51 | 9.28 |
| 2012-09-30 | 2.95 | -12.23 | 4.49 | 10.68 |
| 2012-06-30 | 2.90 | -13.66 | 4.47 | 12.09 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Starpharma Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Starpharma Holdings has efficiently used its assets last year compared to the AU Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Starpharma Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Starpharma Holdings's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Starpharma Holdings has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
SPL Health
How is Starpharma Holdings's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Starpharma Holdings's finances.
The net worth of a company is the difference between its assets and liabilities.
- Starpharma Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Starpharma Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 1420.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Starpharma Holdings Company Filings, last reported 4 months ago.
| Date (Data in AUD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 47.90 | 0.04 | 44.40 |
| 2018-09-30 | 47.90 | 0.04 | 44.40 |
| 2018-06-30 | 53.28 | 0.05 | 51.32 |
| 2018-03-31 | 53.28 | 0.05 | 51.32 |
| 2017-12-31 | 55.91 | 0.06 | 49.90 |
| 2017-09-30 | 55.91 | 0.06 | 49.90 |
| 2017-06-30 | 60.98 | 0.07 | 61.19 |
| 2016-12-31 | 41.61 | 0.00 | 36.28 |
| 2016-09-30 | 41.61 | 0.00 | 36.28 |
| 2016-06-30 | 49.42 | 0.02 | 45.97 |
| 2016-03-31 | 49.42 | 0.02 | 45.97 |
| 2015-12-31 | 59.42 | 0.03 | 54.69 |
| 2015-09-30 | 59.42 | 0.03 | 54.69 |
| 2015-06-30 | 37.56 | 0.05 | 30.85 |
| 2015-03-31 | 37.56 | 0.05 | 30.85 |
| 2014-12-31 | 46.63 | 0.06 | 39.32 |
| 2014-09-30 | 46.63 | 0.06 | 39.32 |
| 2014-06-30 | 32.95 | 0.08 | 24.03 |
| 2014-03-31 | 32.95 | 0.08 | 24.03 |
| 2013-12-31 | 41.33 | 0.09 | 27.83 |
| 2013-09-30 | 41.33 | 0.09 | 27.83 |
| 2013-06-30 | 45.97 | 0.10 | 33.84 |
| 2013-03-31 | 45.97 | 0.10 | 33.84 |
| 2012-12-31 | 47.89 | 0.11 | 33.18 |
| 2012-09-30 | 47.89 | 0.11 | 33.18 |
| 2012-06-30 | 48.65 | 0.14 | 42.81 |
- Starpharma Holdings's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has been reduced over the past 5 years (0.2% vs 0.1% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Starpharma Holdings has sufficient cash runway for more than 3 years based on current free cash flow.
- Starpharma Holdings has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -21.1% each year.
Financial health checks
We assess Starpharma Holdings's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Starpharma Holdings has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
SPL Dividends
What is Starpharma Holdings's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
A$2,000 of
Starpharma Holdings
shares you are expected to receive
A$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Starpharma Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Starpharma Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Global Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 143 Stocks | 3% |
| Australia Market Average Dividend Yield | Market Cap Weighted Average of 415 Stocks | 4.2% |
| Australia Minimum Threshold Dividend Yield | 10th Percentile | 1.6% |
| Australia Bottom 25% Dividend Yield | 25th Percentile | 2.7% |
| Australia Top 25% Dividend Yield | 75th Percentile | 5.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in A$) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-06-30 | 0.00 | 1.00 |
| 2020-06-30 | 0.00 | 1.00 |
| 2019-06-30 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Starpharma Holdings has not reported any payouts.
- Unable to verify if Starpharma Holdings's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Starpharma Holdings's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Starpharma Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Starpharma Holdings has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
SPL Management
CEO
| COMPENSATION | A$1,692,817 |
| AGE | 55 |
| TENURE AS CEO | 12.8 years |
CEO Bio
Dr. Jacinth K. Fairley, also known as Jackie, B.Sc., B.V.Sc.(Hons), MBA, GAICD, FTSE has been the Chief Executive Officer of Starpharma Holdings Limited since July 1, 2006 and serves as its Managing Director. Previously, Dr. Fairley served as the Chief Operating Officer of Starpharma Holdings Limited from July 4, 2005 to June 30, 2006. She served as Chief Executive Officer and Managing Director of Cerylid Biosciences Ltd. from 2001 to 2005. She has been Independent Non-Executive Director of Mirrabooka Investments Limited since February 15, 2018. She has over 25 years of experience working in the pharmaceutical and biotechnology industries. Dr. Fairley held a variety of international business development and senior management roles with various companies, including CSL and Faulding (which is now Mayne Pharma). She served as Vice President of International Business Development of Faulding’s Hospital Business for five years and she gained extensive international experience in product and technology licensing deals and managed Faulding’s global injectable development program. She has over twelve years of experience in the pharmaceutical and animal health industries with CSL Ltd. and F. H. Faulding and Co. She was a practicing veterinary surgeon prior to joining CSL in 1989. She has been an Executive Director of Starpharma Holdings Ltd since July 1, 2006. She serves as a board member of the Melbourne Business School and is a past member of the Federal Government’s Pharmaceutical Industry Working Group and the Federal Ministerial Biotechnology Advisory Council. She was the recipient of the prestigious Clemenger Medal and a number of other academic prizes. She is also a Graduate of the Australian Institute of Company Directors. Dr. Fairley holds BSc (Hons) with Pharmacology and Pathology and Bachelor of Veterinary Science degrees from Melbourne University. Dr. Fairley also obtained an MBA from the Melbourne Business School.
CEO Compensation
- Jackie's compensation has increased whilst company is loss making.
- Jackie's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure
Average tenure of the Starpharma Holdings management team in years:
- The average tenure for the Starpharma Holdings management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team
Jackie Fairley
CEO, MD & Executive Director
A$2M
55
12.8 yrs
Nigel Baade
CFO & Company Secretary
A$531K
10.3 yrs
Tony Eglezos
Vice President of Business Development
A$540K
5.8 yrs
Jeremy Paull
Vice President of Development & Regulatory Affairs
A$582K
David Owen
Vice President of Research
A$532K
13.3 yrs
Board of Directors Tenure
Average tenure and age of the Starpharma Holdings board of directors in years:
- The tenure for the Starpharma Holdings board of directors is about average.
Board of Directors
Rob Thomas
Chairman
A$130K
73
4.9 yrs
Jackie Fairley
CEO, MD & Executive Director
A$2M
55
12.8 yrs
Zita Peach
Independent Non Executive Director
A$74K
53
7.6 yrs
Peter Turvey
Independent Non-Executive Director
A$74K
7.2 yrs
Dick Hazleton
Independent Non-Executive Director
A$73K
76
12.4 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (A$) | Value (A$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 30. Apr 19 | Sell | FIL Limited | Company | 29. Mar 19 | 26. Apr 19 | -956,045 | A$1.33 | A$-1,271,540 | ||
| 30. Apr 19 | Buy | FIL Limited | Company | 10. Jan 19 | 14. Mar 19 | 737,642 | A$1.15 | A$846,458 | ||
| 13. Jan 19 | Buy | FIL Limited | Company | 09. Jan 19 | 09. Jan 19 | 172,604 | A$1.12 | A$192,626 | ||
| 28. Dec 18 | Buy | Peter Turvey | Individual | 28. Dec 18 | 28. Dec 18 | 30,000 | A$0.96 | A$28,800 | ||
| 28. Dec 18 | Buy | Jacinth Fairley | Individual | 28. Dec 18 | 28. Dec 18 | 30,000 | A$0.93 | A$28,035 | ||
| 28. Dec 18 | Buy | Robert Thomas | Individual | 28. Dec 18 | 28. Dec 18 | 50,000 | A$0.96 | A$48,000 | ||
| 26. Dec 18 | Sell | FIL Limited | Company | 20. Dec 18 | 20. Dec 18 | -298,792 | A$1.40 | A$-418,339 | ||
| 10. Dec 18 | Buy | FIL Limited | Company | 10. Oct 18 | 06. Dec 18 | 778,586 | A$1.56 | A$1,217,397 | ||
| 07. Oct 18 | Sell | FIL Limited | Company | 12. Sep 18 | 03. Oct 18 | -3,291,851 | A$1.57 | A$-4,936,896 | ||
| 13. Sep 18 | Sell | FIL Limited | Company | 29. Jun 18 | 11. Sep 18 | -3,759,915 | A$1.42 | A$-5,339,079 | ||
| 05. Jun 18 | Sell | FIL Limited | Company | 14. Jun 16 | 01. Jun 18 | -9,405,363 | A$1.64 | A$-15,424,790 | ||
Management checks
We assess Starpharma Holdings's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Starpharma Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
SPL News
Simply Wall St News
What Kind Of Shareholders Own Starpharma Holdings Limited (ASX:SPL)?
The big shareholder groups in Starpharma Holdings Limited (ASX:SPL) have power over the company. … Insider Ownership Of Starpharma Holdings The definition of an insider can differ slightly between different countries, but members of the board of directors always count. … General Public Ownership The general public, who are mostly retail investors, collectively hold 55% of Starpharma Holdings shares.
Simply Wall St - – Full articleStarpharma Holdings (ASX:SPL) Shareholders Have Enjoyed A 41% Share Price Gain
It might be of some concern to shareholders to see the Starpharma Holdings Limited (ASX:SPL) share price down 10% in the last month. … Starpharma Holdings isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Over the last three years Starpharma Holdings has grown its revenue at 5.6% annually.
Simply Wall St - – Full articleHow Much Did Starpharma Holdings Limited's (ASX:SPL) CEO Pocket Last Year?
Jackie Fairley has been the CEO of Starpharma Holdings Limited (ASX:SPL) since 2006. … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Jackie Fairley's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleHave Insiders Been Buying Starpharma Holdings Limited (ASX:SPL) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So before you buy or sell Starpharma Holdings Limited (ASX:SPL), you may well want to know whether insiders have been buying or selling. … In the last twelve months there was more buying than selling by Starpharma Holdings insiders
Simply Wall St - – Full articleWhat Did Starpharma Holdings Limited's (ASX:SPL) CEO Take Home Last Year?
Jackie Fairley has been the CEO of Starpharma Holdings Limited (ASX:SPL) since 2006. … Our data indicates that Starpharma Holdings Limited is worth AU$613m, and total annual CEO compensation is AU$2m. … It would therefore appear that Starpharma Holdings Limited pays Jackie Fairley more than the median CEO remuneration at companies of a similar size, in the same market
Simply Wall St - – Full articleWhy Starpharma Holdings Limited's (ASX:SPL) Ownership Structure Is Important
Today, I will be analyzing Starpharma Holdings Limited’s (ASX:SPL) recent ownership structure, an important but not-so-popular subject among individual investors. … Ownership structure of a company has been found to affect share performance over time. … Therefore, it is beneficial for us to examine SPL's ownership structure in more detail.
Simply Wall St - – Full articleDoes Starpharma Holdings Limited's (ASX:SPL) Recent Track Record Look Strong?
Assessing Starpharma Holdings Limited's (ASX:SPL) past track record of performance is an insightful exercise for investors. … Today I will assess SPL's recent performance announced on 31 December 2017 and evaluate these figures to its long-term trend and industry movements. … SPL is loss-making, with the most recent trailing twelve-month earnings of -AU$13.11m (from 31 December 2017), which compared to last year has become.
Simply Wall St - – Full articleDid Starpharma Holdings Limited's (ASX:SPL) Earnings Growth Outperform The Industry?
See our latest analysis for Starpharma Holdings Did SPL's recent earnings growth beat the long-term trend and the industry? … ASX:SPL Income Statement May 15th 18 We can further analyze Starpharma Holdings's loss by looking at what the industry has been experiencing over the past few years. … This means that even though Starpharma Holdings is presently running a loss, whatever near-term headwind the industry is facing, Starpharma Holdings is relatively better-cushioned than its peers.What does this mean?
Simply Wall St - – Full articleStarpharma Holdings Limited (ASX:SPL): Is Breakeven Near?
Many investors are wondering the rate at which SPL will turn a profit, with the big question being “when will the company breakeven?” In this article, I will touch on the expectations for SPL’s growth and when analysts expect the company to become profitable. … Check out our latest analysis for Starpharma Holdings SPL is bordering on breakeven, according to analysts. … Using a line of best fit, I calculated an average annual growth rate of 117.71%, which signals high confidence from analysts.
Simply Wall St - – Full articleWhat Is Starpharma Holdings Limited's (ASX:SPL) Share Price Doing?
Starpharma Holdings Limited (ASX:SPL), a pharmaceuticals company based in Australia, saw significant share price volatility over the past couple of months on the ASX, rising to the highs of A$1.64 and falling to the lows of A$1.32. … According to my valuation model, Starpharma Holdings seems to be fairly priced at around 9.20% below my intrinsic value, which means if you buy Starpharma Holdings today, you’d be paying a fair price for it. … Furthermore, Starpharma Holdings’s share price also seems relatively stable compared to the rest of the market, as indicated by its low beta.
Simply Wall St - – Full articleSPL Company Info
Description
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Details
| Name: | Starpharma Holdings Limited |
| SPL | |
| Exchange: | ASX |
| Founded: | 1996 |
| A$477,627,235 | |
| 371,694,347 | |
| Website: | http://starpharma.com |
| Address: |
Starpharma Holdings Limited 4-6 Southampton Crescent, Abbotsford, Victoria, 3067, Australia |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ASX | SPL | Ordinary Shares | Australian Securities Exchange | AU | AUD | 28. Sep 2000 | |
| OTCPK | SPHR.F | Ordinary Shares | Pink Sheets LLC | US | USD | 28. Sep 2000 | |
| DB | PQ6 | Ordinary Shares | Deutsche Boerse AG | DE | EUR | 28. Sep 2000 | |
| CHIA | SPL | Ordinary Shares | Chi-X Australia | AU | AUD | 28. Sep 2000 | |
| OTCPK | SPHR.Y | SPONSORED ADR | Pink Sheets LLC | US | USD | 20. Jan 2005 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/21 10:32 |
| End of day share price update: | 2019/05/21 00:00 |
| Last estimates confirmation: | 2019/04/04 |
| Last earnings filing: | 2019/02/26 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
